Catalytically-active gelatinase mutant

Details Catalytically-active gelatinase mutant Catalytically-active gelatinase mutant

1994-12-16

2001-02-27

Achutamurthy, Ponnathapua (Department: 1652)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Hydrolase

C435S183000, C536S023200

Reexamination Certificate

active

06194189

ABSTRACT:

BACKGROUND OF THE INVENTION
The present invention relates to a truncated mutant of the 92 kDa gelatinase which is catalytically active comparable to the full protein but, unlike the full protein, is essentially inactive against insoluble elastin.
The truncated mutant of the invention is useful for treatment of disorders requiring the removal of excess connective tissue, e.g., keloids, post-operative fibrosis, intervertebral disc injections, hypertrophic scars, wound debridement, post-surgical adhesions and various fibrotic diseases (scleroderma, idiopathic pulmonary fibrosis) and the like treatments.
(Note: Literature references on the following background information, and on conventional test methods and laboratory procedures well known to the ordinary person skilled in the art, and other such state-of-the-art techniques as used herein are indicated in parentheses, and appended at the end of the specification.)
Elastin is an extracellular matrix protein composed of hydrophobic tropoelastin monomers that are highly crosslinked. Elastin provides resilience to elastic fibers. The hydrophobicity of tropoelastin monomers, as well as their extensive crosslinking, result in an insoluble elastic fiber which is highly resistant to proteolysis (1). In the normal physiologic state, elastin undergoes minimal turnover (2). However, pathologic situations exist including pulmonary emphysema (3) and abdominal aortic aneurysm (4) which are characterized by proteolytic destruction of elastic fibers.
The matrix metalloproteinases comprise a gene family of enzymes that collectively are capable of degrading all components of extracellular matrix in physiologic and pathologic states (5). These enzymes are organized into homologous domain structures, with some differences in number of domains. All members share a zymogen domain and a zinc-binding catalytic domain. As presently recognized, this family consists of fibroblast, neutrophil, and a breast carcinoma-derived (6) collagenase, a 92 kDa gelatinase (also called gelatinase B and MMP-9), a 72 kDa gelatinase (also called gelatinase A and MMP-2), three stromelysins, macrophage metalloelastase, matrilysin (also known as PUMP and MMP-7), and a recently described 66 kDa membrane-type metalloproteinase (7). Four members of this gene family have the capacity to degrade insoluble elastin. These are the 92 kDa gelatinase (8,9), the 72 kDa gelatinase (8,9), matrilysin (9), and macrophage metalloelastase
The issue of substrate specificity has received considerable attention recently in matrix metalloproteinase biology. The structural determinants within these enzymes which confer the ability to degrade various substrates appear to be localized within discrete domains. For example, the ability of the collagenases to degrade triple-helical collagen requires the presence of the C-terminal hemopexin-like domain (12-14). In contrast, the stromelysins degrade a variety of substrates in a manner which is independent of the C-terminal hemopexin-like domain (13, 15-17). Unique to the 72 kDa and 92 kDa gelatinases is an additional domain composed of three fibronectin type II repeats inserted in tandem within the zinc-binding catalytic domain. This fibronectin-like domain is required for the gelatinases to bind efficiently to type I gelatin and type IV collagen (18-21). Matrilysin is the simplest member of this family of enzymes in that it contains only a zymogen domain and a catalytic zinc-binding domain.
A 92 kDa type IV collagenase (gelatinase) and the CDNA clone representing the full-length protein is disclosed in U.S. Pat. No. 4,992,537.


REFERENCES:
patent: 4992537 (1991-02-01), Goldberg
patent: 5270447 (1993-12-01), Liotta et al.
Senior et al., J. Biol. Chem. 266, 7870-75 (1991).
Murphy et al., Biochem. J. 277, 277-279 (1991).
Collier et al., J Biol. Chem. 267, 6776-6781 (1992).
Murphy et al., J. Biol. Chem. 269, 6632-6636 (1994).
Willenbrock et al., Biochemistry 32, 4330-37 (1993).
Wilhelm et al. J. Biol. Chem. 264, 17213-21 (1989).
Murphy et al., J. Biol. Chem. 267, 9612-9618 (1992).
O'Connell, J.P. et al. (1994) “Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B”J. Biol. Chem. 269:14967-14973.
Sequence comparison between SEQ ID No:1 and human metalloproteinase PUMP-1.
Hirel, P.-H. et al. (1989) “Extent of N-terminal methionine excision from Escherichia coli proteins is governed by the side-chain length of the penultimate amino acid” Proc. Nat'l. Acad. Sci., USA 86:8247-8251, Nov. 1989.
Thomas, J. et al. (1991) “Expression in Escherichia coli and characterization of the heat-stable inhibitor of the cAMP-dependent protein kinase” J. Biol. Chem. 266(17):10906-10911, Jun. 1991.

Affiliated with

Also associated with

Rating

Catalytically-active gelatinase mutant does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Catalytically-active gelatinase mutant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Catalytically-active gelatinase mutant will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2581211